Key result
This review addresses the arguments for and against the use of CK-MB in emergency department decision-making for patients presenting with chest pain.
Why the study?
Does the use of CK-MB improve the diagnosis of myocardial infarction in patients presenting to the emergency department with chest pain?
Does the use of CK-MB improve the diagnosis of myocardial infarction in patients presenting to the emergency department with chest pain?
This review discusses the utility and limitations of using CK-MB as a cardiac biomarker for diagnosing myocardial infarction in the emergency department.
Answers are grounded in this paper and cite their sources.
CK-MB utility in ED chest pain evaluation remains uncertain; leaves open its incremental value versus high-sensitivity troponin in contemporary practice.
The diagnosis of myocardial infarction (Ml) in patients presenting to the emergency department (ED) represents a clinical challenge. The multitude of potential chest discomfort diagnoses and the lack of unique clinical features for Ml make treatment and disposition of chest discomfort patients without classic electrocardiographic (ECG) changes problematic.' 2 The fact that cardiac serum markers such as creatine kinase-MB-isoenzyme (CK-MB) can be used to diagnose Ml in the hospital setting has led investigators to reconsider the application of cardiac enzymes to ED decisionmaking. The present paper addresses the arguments for and against use of CK-MB in the ED in the light of new technology and recent clinical data.
No takes yet. Share an insight, caveat, or question.
Jerris R. Hedges (1995) conducted a review in Myocardial infarction / chest pain. CK-MB testing was evaluated. This review addresses the arguments for and against the use of CK-MB in emergency department decision-making for patients presenting with chest pain.
Synapse has enriched 10 related papers. Consider them for comparative context: